---
title: "CStone secures FDA clearance to begin CS2009 Phase II trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276114397.md"
description: "CStone Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase II trial for its trispecific antibody CS2009, targeting PD-1, VEGFA, and CTLA-4 in patients with advanced solid tumors. The trial will assess safety, efficacy, pharmacokinetics, and tolerability, with 15 cohorts planned across nine tumor types. CStone's CEO highlighted the productive interaction with the FDA, which reviewed Phase I data and aligned on Phase II study design. Recruitment is ongoing in China and Australia, with the US clearance now obtained."
datetime: "2026-02-17T10:57:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276114397.md)
  - [en](https://longbridge.com/en/news/276114397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276114397.md)
---

# CStone secures FDA clearance to begin CS2009 Phase II trial

CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4. Credit: Michele Ursi / Shutterstock.com.

CStone Pharmaceuticals has received the US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application, enabling the company to initiate a Phase II clinical trial of CS2009, its trispecific antibody, in patients with advanced solid tumours.

The ongoing global trial uses a parallel, multi-cohort expansion design. It will examine the safety, efficacy, pharmacokinetics and tolerability of CS2009 as both monotherapy and in combination regimens.

Recruitment is ongoing in China and Australia, with IND clearance now obtained in the US.

Free Sample

### Download sample pages of selected reports

Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.

A total of 15 cohorts are planned across nine solid tumour indications, including cervical cancer (CC), extensive-stage small cell lung cancer (ES-SCLC), gastric or gastroesophageal junction cancer (GC/GEJC), ovarian cancer (PROC), and triple-negative breast cancer (TNBC).

CS2009 is an antibody targeting programmed cell death protein 1 (PD-1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

According to CStone, it is designed to deliver anti-tumour effects on multiple fronts by combining three clinically validated targets within a single agent.

CStone CEO, R&D president and executive director Dr Jason Yang said: “This milestone follows a productive interaction with the agency, during which they reviewed our comprehensive Phase I data, including safety and anti-tumour activity data collected during dose escalation and expansion, and provided alignment on key elements of the Phase II study design, including dose optimisation and expansion strategies.

“We are now actively advancing the CS2009 clinical programme globally and look forward to sharing further updates as the study progresses.”

In March 2025, CStone dosed the first subject in the multi-centre Phase I trial of CS2009.

### Unlock up to 35% savings on GlobalData reports

Use the code at checkout in the report store

-   ### 20% OFF
    
    Buy 2 reports
    
    Use code:
    
    #### Bundle20
    
-   ### 25% OFF
    
    Buy 3 reports
    
    Use code:
    
    #### Bundle25
    
-   ### 30% OFF
    
    Buy 4 reports
    
    Use code:
    
    #### Bundle30
    
-   ### 35% OFF
    
    Buy 5+ reports
    
    Use code:
    
    #### Bundle35
    

Valid on all reports priced $995 and above. Cannot be combined with other offers.

#### Still deciding what will work best for your business?

Ask our experts for help.

Enquire before buying

### Related Stocks

- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)

## Related News & Research

- [08:09 ETIterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting](https://longbridge.com/en/news/282541691.md)
- [09:30 ETMichael Foods Introduces Three New Breakfast Innovations for Spring 2026](https://longbridge.com/en/news/282701292.md)
- [Novel Drugs Approved By The FDA In 2025](https://longbridge.com/en/news/282341088.md)
- [Novo Nordisk Expands Workforce After Deep Cuts](https://longbridge.com/en/news/283036289.md)